The MAPKs are a family of serine/threonine kinases that play an essential role in connecting cell-surface receptors to changes in transcriptional programs. MAPKs are part of a three-component kinase module consisting of a MAPK, an upstream MEK, and a MEKK that couples the signals from cell-surface receptors to trigger downstream pathways.
The MAPKs are a family of serine/threonine kinases that play an essential role in connecting cell-surface receptors to changes in transcriptional programs ( Fig. 1) [1] . They are expressed ubiquitously and are involved in the regulation of a wide variety of critical cellular functions, including proliferation, differentiation, migration, and apoptosis [2] [3] [4] [5] [6] [7] . In humans, there are at least 11 members of the MAPK superfamily, which can be divided into six distinct subgroups based on sequence similarity: (a) ERK1, ERK2; (b) JNK1, JNK2, JNK3; (c) p38MAPKs (p38␣/␤/␥/␦); (d) ERK5; (e) ERK3 s; and (f) ERK7 s [4, 8] . Each group of MAPKs is activated by a distinct kinase cascade in which a MAP3K or MEKK phosphorylates and activates a downstream dual-specificity MAP2K or MEK, which in turn stimulates MAPK activity through dual phosphorylation on threonine and tyrosine residues within a conserved tripeptide motif (Thr-X-Tyr) [9] . Phosphorylation of these threonine and tyrosine residues on MAPKs results in a conformational change that increases substrate accessibility and enhances catalysis. Activation of ERK is through phosphorylation by MEK (MAPK/ERK kinase) 1/2 in response to various cytokines and growth factors and mediates mitogenic and antiapoptotic signals primarily, whereas members of the JNK and p38 family of MAPKs were identified originally as mediators of cellular stress and are activated by MKK4/MKK7 and MKK3/MKK6, respectively [1] . This review will focus primarily on recent progress in understanding the function of the ERK, JNK, and p38MAPK in regulating hematopoiesis in general and myelopoiesis in particular.
SPECIFICITY IN MAPK ACTIVATION AND FUNCTION
MAPKs are activated by a plethora of extracellular stimuli, often with a single stimulus activating multiple subgroups, implying, however, that there is tight and specific control of MAPK activation and function in response to cellular agonists. MAPKs bind their upstream MAP2Ks and downstream targets through specific surface interactions that are achieved through docking motifs located outside of the catalytic domain [10 -12] . These binding sites or D-motifs are critical in determining substrate specificity of MAPKs. D-motifs are frequently located N-termi-nal to the typical MAPK conserved phosphorylation sites, which are composed of a serine or threonine residue followed by a proline, and the amino acids surrounding these sites further increase the specificity of recognition. In addition, binding of MAPK signaling complexes to scaffold proteins determines the location and duration of MAPK activation, thus regulating specific signaling outcomes [13] (Table 1) .
For instance, the JIP1 protein functions as a scaffold that organizes JNK1/2, MKK7, and the MAP3K MLK1 into a specific MAPK signaling module. Similar to JIP1, additional scaffold proteins such as JIP2, JIP3, and Axin promote assembly of specific signaling complexes involved in the JNK activation [31] . MP1, another scaffold protein, interacts specifically with ERK1 and MEK1, thereby facilitating ERK1 activation [16, 32] . This illustrates how a distinct scaffold protein such as MP1, involved in activation of ERK1 but not ERK2, can confer signaling specificity through recruiting the different components of a specific pathway simultaneously. Recently, KSR-1 was also identified as a scaffold regulating the ERK MAPK pathway [33] . KSR-1 can interact with Raf-1, MEK1/2, and ERK1/2, and some fractions of MEK1/2 were found to remain associated with KSR in quiescent cells. Upon activation by Ras, KSR translocates with MEK1/2 to the plasma membrane, bringing MEK1/2 in close proximity to its activator Raf-1 and its downstream effector ERK1/2, thereby facilitating formation of a Raf/MEK/ERK complex and activation of ERK1/2 [13, 34] . So far, few scaffolds have been described for members of the p38MAPK pathway. However, some of the JNK scaffolding proteins also appear to scaffold components of the p38MAPK pathway as well. For example, it has been demonstrated that JIP2 can facilitate p38 signaling by binding to p38␣ and p38␦ [25, 35] . Furthermore, OSM, a specific scaffold for the p38MAPK pathway, was found to bind to MEKK3, MEK3, and p38 and facilitate p38 activation in response to osmotic stress [30] .
Lastly, the regulated dephosphorylation of MAPKs by phosphoprotein phosphatases also plays an important role in determining the magnitude and duration of kinase activation and thereby the outcome of signaling [31, 36] . Phosphoprotein phosphatases involved in the regulation of MAPK signaling can be classified in three groups based on preference for dephosphorylating: phosphotyrosine, phosphoserine/-threonine, or DSP, which can dephosphorylate both types of residues. DSPs, which selectively inactivate MAPKs, are known as MKPs [36] , which have a variety of subcellular locations and can recognize a single class of MAPK or can regulate more than one MAPK pathway. For example, the cytoplasmic DSP MKP-3 selectively inactivates ERK1/2, whereas nuclear MKP-1 is able to dephosphorylate ERK, JNK, and p38. Together, these mechanisms cooperate to generate specificity in MAPK activation and function. : CONTROLLING THE  BALANCE AMONG EXPANSION,  SURVIVAL, AND DIFFERENTIATION OF  HEMATOPOIETIC PROGENITORS   ERK1 and ERK2, also known as p44 MAPK and p42 MAPK , respectively, were identified as growth factor-stimulated protein kinases phosphorylating MAP-2 and myelin basic protein [37] . They have more than 80% aa sequence similarity and can be activated by a wide variety of stimuli, including growth factors, serum, ligands for heterotrimeric G protein-coupled receptors, cytokines, and osmotic and other cell stresses [38 -40] . Upon activation, ERK1/2 phosphorylate and regulate the activity of cytoplasmic molecules and nuclear proteins, which in turn can control gene expression [41] (Table 2) .
THE ERK PATHWAY
For example, ERK1/2 have been found to phosphorylate [1] p90 RSK, MSK, and MNK [2] , proteins involved in migration, cell attachment, including paxillin and calpain, and [3] transcription factors such as Elk-1, c-Fos, and c-Myc [31] .
The ability of the ERK MAPK signaling module to promote cellular proliferation and survival has now been well established [82, 83] . However, in vivo analysis of ERK1/2 function MAPKs are part of a threecomponent kinase module consisting of a MAPK, an upstream MEK, and a MEKK that couples the signals from cell-surface cytokine receptors to trigger downstream pathways. Three major groups of MAPKs have been characterized in mammals, including ERKs, JNKs, and p38MAPKs. Each group of MAPK is activated by a distinct kinase cascade in which a MAP3K or MEKK phosphorylates and activates a downstream dual-specificity MAP2K or MEK, which in turn stimulates MAPK activity through dual phosphorylation on threonine and tyrosine residues within a conserved tri-peptide motif (Thr-X-Tyr). Upon activation, MAPK itself can phosphorylate specific target substrates on serine and threonine residues. through generation of null mutant mouse strains by gene targeting revealed that ERK signaling is also critically involved in the regulation of other important cellular processes ( Table 3) . ERK1 -/-mice are viable, fertile, and of normal size, indicating that ERK2 may compensate for its loss [84] . However, although ERK1 is apparently dispensable during embryonic development, deletion of ERK2 was found to be embryonic-lethal as a result of defects in trophoblast formation, mesoderm differentiation, and placental function, demonstrating distinct biological functions for these related kinases [85, 86, 96] .
In the hematopoietic system, the ERK pathway has been demonstrated to be essential for thymocyte differentiation, as mice lacking ERK1 manifest impaired proliferation and maturation of thymocytes, despite expression of ERK2 [84] . Furthermore, ex vivo studies focusing on ERK1/2 function using differentiation-competent cell lines revealed the importance of the ERK signaling module in regulating myeloid, erythroid, as well as megakaryocyte differentiation [97] [98] [99] [100] . Experiments using pharmacologic inhibitors have demonstrated that the MEK-ERK pathway is also essential for PMA-induced differentiation of K562 [101, 102] , TF-1 [103] , and U937 cells [104] . Furthermore, ERK1/2-mediated phosphorylation of the C/EBP␣ transcription factor on serine residue 21 was found to regulate negatively the activity of C/EBP␣ and its ability to induce neutrophil differentiation [105] . Although the dephosphorylated form of C/EBP␣ was able to induce neutrophil differentiation, ectopic expression of the phosphomimetic C/EBP␣ mutant inhibited neutrophil differentiation, suggesting that ERK signaling may indeed play a significant role in the regulation of myelopoiesis. Similarly, the requirement for MEK-ERK activation has been demonstrated during cytokine-induced differentiation using human CD34ϩ hematopoietic progenitors (C. R. Geest et al., submitted). Modulating the duration and extent of ERK activation was shown to determine the balance between expansion and survival of hematopoietic progenitors during neutrophil differentiation. The underlying molecular mechanism was found to involve regulation of expression of a variety of cell-cycle-modulating proteins, including c-myc, c-fos, p21CIP1, cyclin D1, and cyclin D3. Furthermore, conditional activation of MEK1 also resulted in increased expression of mRNA transcripts, encoding a large number of hematopoietic cytokines that may act as autocrine growth factors to activate signaling pathways implicated in regulating expansion and survival of hematopoietic progenitor cells. Although found to be an essential regulator of expansion and survival of myeloid progenitors, conditional activation of MEK1 did not affect terminal differentiation of neutrophil progenitors. However, a recent study indicates that ERK MAPK signaling may actually be involved in the regulation of early myeloid commitment of HSCs [106] . In vitro, GM colony formation of murine HSCs in the presence of MEK-ERK pharmacological inhibitors was inhibited, whereas HSCs ectopically expressing active MEK1 showed increased percentages of macrophage antigen-1ϩ myeloid cells.
In addition, it has been demonstrated recently that ERK1/2-mediated phosphorylation is implicated in the degradation of active GATA-1, a transcription factor that plays a critical role in regulating erythroid, megakaryocytic, and eosinophil development [107, 108] . Acetylation of GATA-1 was found to stimulate DNA binding and enhance GATA-1-dependent transcription as well as target GATA-1 for degradation by the ubiquitinproteasome pathway [107] . However, acetylation of GATA-1 alone was not sufficient to cause degradation, but rather, additional phosphorylation on ERK1/2-specific residues was required. Together, this suggests that acetylated, active GATA-1 remains at promoters until its degradation is triggered in response to ERK-mediated phosphorylation. Furthermore, it has been reported that ERK mediates EPO-induced phosphorylation of T cell acute lymphocytic leukemia 1/stem cell leukemia in murine proerythroblasts, a transcription factor belonging to the family of the helix-loop-helix class of transcription factors, which is essential for erythropoiesis [109, 110] .
In contrast to most experimental cell systems, undifferentiated ES cells do not require the ERK pathway for proliferation and self-renewal [111, 112] . Remarkably, inhibition of MEK-ERK MAPK actually promotes self-renewal of murine ES cells, [30] and dependency on the ERK pathway only becomes apparent upon lineage commitment. Although the molecular basis of how ERK potentiates lineage commitment is poorly defined, it has been proposed that ERK1/2 activation may somehow act as a stimulus for naïve ES cells to exit the self-renewal program and facilitate transition to a state that is responsive to inductive stimuli [113] . Murine embryos deficient for MAP3K B-Raf indeed have a quantitative defect in fetal liver hematopoietic progenitor cell development; however, the relative progenitor frequency was not affected in the absence of B-Raf, suggesting that B-Raf plays a critical role in establishing the proper number of myeloid progenitors in the fetal liver [114] . Additional data suggest that this phenotype is a result of the loss of associated ERK1/2 activation during hematopoietic progenitor cell formation. In addition to its effect on hematopoietic progenitor development, TPO-induced expansion of ES cell-derived megakaryocytic progenitors and suppression of mast cell development are abrogated in the absence of B-Raf. We (C. R. Geest et al., submitted) and others [115] have demonstrated recently that ERK MAPK activity is essential for survival of erythroid CD34 ϩ progenitors. Inhibition of ERK1/2 activity completely abolished expansion and subsequent differentiation of CD34 ϩ erythrocyte progenitors as a result of induction of apoptosis. This was found further to correlate with abrogation of antiapoptotic Bcl-xL levels in CD34 ϩ cells treated with the MEK1/2 inhibitor, indicating that MEK-ERK Substrates include various transcription factors, kinases, as well as other factors that can be regulated directly by MAPK-mediated phosphorylation. The list of indicated substrates is not exhaustive but illustrates many of the important substrates that have been identified currently.
activity is essential for survival and development of erythroid progenitors. Furthermore, recently, it has been reported that UCP2, an inner membrane mitochondrial protein that has been implicated in the regulation of erythropoiesis, modulates expansion of erythrocyte progenitors in a MEK-ERK pathwaydependent manner. Analysis of progenitor cells from bone marrow and fetal liver from UCP2-deficient mice revealed that UCP2 deficiency results in a significant decrease in cell proliferation at the EPO-dependent early phase of erythropoiesis. This was accompanied by reduction in the phosphorylated form of ERK, suggesting that UCP2 is modulating proliferation during erythropoiesis through regulation of ERK activation [116] . Consistently, with a key role of ERK1/2 in regulating erythropoiesis, TRAIL was found to regulate negatively erythroid maturation of CD34 ϩ -derived erythroid progenitors through an ERK-dependent pathway [117] . Remarkably, although previous studies showed that ERK MAPK activity is indispensable during erythropoiesis, inhibitory effects of TRAIL on erythroid maturation were reverted upon addition of a pharmacologic inhibitor of the ERK pathway. Thus, this suggests that antidifferentiative effects of TRAIL on erythroblasts are indeed mediated through activation of the MEK-ERK pathway.
Taken together, these results suggest that correct activation of the ERK pathway is required for normal hematopoiesis, and modulation of the duration and extent of ERK activation seems to be an important factor in regulating the ultimate balance among expansion, survival, and differentiation of hematopoietic progenitors.
THE JNK PATHWAY IS ESSENTIAL FOR NORMAL ERYTHROPOIESIS
The JNK MAPKs, also known as stress-activated protein kinases, were discovered originally by their ability to phosphorylate the N-terminal transactivating domain of the transcription factor c-Jun [118] . Three distinct genes, JNK1, JNK2, and JNK3, encoding 10 isoforms, have now been identified in mammals [119 -121] . JNK1 and JNK2 are expressed ubiquitously, and expression of the JNK3 isoform is restricted primarily to the brain, testis, and heart [5] . JNKs are activated in response to inflammatory cytokines, growth factors, DNA and protein synthesis inhibition, and environmental stresses, such as heat, ionizing radiation, DNA damage, and oxidant stress. Downstream substrates of JNKs include the transcription factors c-Jun, Elk-1, p53, ATF-2, and NFAT; MAPs; and proapoptotic Bcl-2 family members, including Bid, Bax, and Bim (Table 2) [31, 122] .
The generation of mice deficient in one or more of the JNK genes has facilitated the functional analysis of the role of JNKs (Table 3) . Mice lacking individual members of the JNK family are viable; however, JNK1 and JNK2 knockouts exhibit defects in T cell activation and apoptosis of immature thymocytes [87] . In contrast, embryos deficient of JNK1 and JNK2 die early during embryonic development (E11.5-12.5) as a result of neural tube closure and brain defects. In addition, JNK1Ϫ/Ϫ JNK2Ϫ/Ϫ embryonic fibroblasts are resistant to stress-induced apoptosis, suggesting a role of JNK1 and JNK2 in regulating apoptosis in response to environmental stress [123] . Mice lacking JNK3, which is expressed mainly in the nervous system, are more resistant to glutamate receptor agonist kainate-induced apoptosis of neurons in the hippocampus [90] . The same phenotype is exhibited by "knock-in" mice with mutations in the two c-Jun phosphorylation sites (Ser-63/ 73), indicating that JNK3 may exert its effect through c-Jun [124] . In addition, the early embryonic death caused by the targeted deletion of the MKK4 or MKK7 genes in mice further supports an essential role for the JNK MAPK signaling pathway in the regulation of developmental processes [122] .
Although JNK proteins were first identified as kinases that were activated by a stress-and apoptosis-inducing agent, JNKs are now known to be activated by a variety of growth factors that regulate proliferation, differentiation, and survival of hematopoietic cells, including EPO and SCF, as well as TPO, IL-3, and GM-CSF [125] [126] [127] . Furthermore, several studies focusing on JNK function in hematopoietic cell systems revealed the importance of the JNK signaling module in regulating erythropoiesis [128 -130] . Homologous deletion of JNK1 or JNK2 in mice has no apparent effect on hematopoiesis, which might be explained by redundancy of the different JNK isoforms. In contrast, activation of JNK signaling has been implicated in the regulation of erythroid proliferation and survival. Treatment with the JNK1/2/3 inhibitor SP600125 inhibited EPO-dependent proliferation of several differentiation-competent erythroid cell lines [128] . Furthermore, inhibition of JNK activity in primary mouse bone marrow cells reduced the number of BFU-E, whereas the more differentiated CFU-E were not affected. In addition, SP600125 protected the BFU-Es from apoptosis induced by cytosine arabinoside, demonstrating that JNK activity appears to be an important regulator of proliferation in immature, primary erythroid cells and these erythroid cell lines but presumably may not be required for the survival or proliferation of CFU-Es or proerythroblasts [129] . Moreover, it has been reported recently that disruption of the upstream JNK regulator MEKK1 causes embryonic death as a result of defects in erythrocyte differentiation, further indicating that the MEKK1-JNK signaling pathway is indeed essential for erythropoiesis [130] .
It has also been demonstrated that the AP-1 transcription factor complex, which is comprised of members of the Jun and Fos families of phosphoproteins, is implicated in the regulation of proliferation and apoptosis of the murine erythroleukemia cell line HCD57 [131] . AP-1 DNA binding activity was induced upon growth factor stimulation and withdrawal; however, different AP-1 factors were found to be involved in the two processes. c-Jun DNA binding activity and JNK activity were induced in the presence of EPO, whereas EPO withdrawal resulted in a decrease in JNK activity and an increase in JunB DNA binding activity .
Besides involvement in the regulation of erythropoiesis, the importance of JNK signaling in the regulation of myeloid differentiation was illustrated by a recent study showing that JNK1 can interact physically with the DBD of C/EBP␣ in vitro and in vivo [132] . C/EBP␣ is a leucine zipper transcription factor that plays a critical role in regulating myelopoiesis, and mice deficient for C/EBP␣ lack mature granulocytes and accumulate immature myeloblasts in the bone marrow [133, 134] . It was reported that active JNK1 inhibits ubiquitination of C/EBP␣, possibly by phosphorylating the DBD, increasing C/EBP␣ protein stability, and altering its conformation, contributing to enhanced C/EBP␣ transcriptional activation. Thus, it is possible that JNK1 acts as positive regulator of C/EBP␣ and that JNK activity is required for C/EBP␣ activation in myeloid progenitors. In contrast, coimmunoprecipitation experiments demonstrated that C/EBP␣ can also interact with c-Jun and JunB [135] , thereby competing with c-Jun for interaction with PU.1, an important transcriptional regulator during monopoiesis [136] . In addition, in murine myeloid progenitors, C/EBP␣:c-Jun or C/EBP␣:c-Fos heterodimers induced monocyte in favor of granulocyte-lineage commitment [135] , suggesting that c-Jun or c-Fos interaction may prevent C/EBP␣-mediated induction of granulocyte differentiation.
In mast cells lacking MKK7, JNK activation is abolished completely and results in hyperproliferation in response to IL-3 and SCF stimulation [137] . Furthermore, MKK7 deficiency reduced expression of JunB and the cell-cycle inhibitor p16INK4a, which resulted in up-regulation of cyclin D1. Reexpression of p16INK4a in MKK7Ϫ/Ϫ mast cells abrogated the hyperproliferative response, indicating that the MKK7-JNK signaling pathway functions as a negative regulator of cell growth in mast cells. Furthermore, gadd45b, a gene induced rapidly in response to genotoxic stress or cytokines, has also been demonstrated to stimulate JNK activity, thereby sensitizing cells for growth arrest and apoptosis. Takekawa and Saito [138] reported that Gadd45-like proteins can activate JNK signaling through binding and activation of MTK1 MAP3K, which is upstream of p38 and JNK MAPKs. However, exposure of Gadd45b-deficient bone marrow cells to UV light was found to result in prolonged JNK activation and increased sensitivity to UV-induced apoptosis, suggesting that in murine bone marrow cells, Gadd45b suppresses JNK activity in response to UV radiation [139] . Although several lines of evidence suggest that in hematopoietic cells, JNK activation is linked to cell death, the exact function of Gadd45 and JNK in the regulation of apoptosis remains unclear. During monocytic differentiation of primary mouse progenitor cells, sustained JNK activation by hematopoietic progenitor kinase 1, a potent activator of the JNK signaling pathway, was found to actually confer progenitor cell survival, independent of the growth factor IL-3 [140] . Together, these studies indicate that JNK signaling is involved in the regulation of normal erythropoiesis and myelopoiesis; however, the precise role of the different JNK family members is defined incompletely currently.
p38MAPK ACTIVITY IS INDISPENSABLE DURING ERYTHROID DEVELOPMENT BUT DETRIMENTAL FOR MYELOPOIESIS
p38␣ was first isolated as a tyrosine-phosphorylated protein in macrophages in response to LPS stimulation [39] . To date, four splice variants of the p38 family have been identified: p38␣, p38␤, p38␥, and p38␦. p38␣ and p38␤ are expressed ubiquitously, whereas expression of p38␥ and p38␦ appears to be more tissue-restricted [7] . Sequence comparisons revealed further that the four p38 isoforms share only ϳ60% identity, suggesting distinct cellular functions. p38MAPKs respond to a variety of extracellular stimuli, particularly cellular stress, such as osmotic shock, UV radiation, hypoxia, inflammatory cytokines, and growth factors [31] . Upon activation, p38MAPKs phosphorylate and regulate a broad variety of substrates, which include [1] transcription factors ATF-1/2, C/EBP␤, STAT1, and STAT3 [2] , protein kinases such as p90 RSK, MAPKAP2 and -3, as well as [3] a variety of other substrates including HSPs (Table 2) [7, [141] [142] [143] .
Although members of the p38 family of MAPKs were also identified originally as mediators of cellular stress, gene disruption and silencing experiments in mice revealed central roles for p38MAPK in multiple developmental processes. p38␣(Ϫ/Ϫ) deficiency is embryonic-lethal, and most embryos die between E10.5 and E12.5 as a result of defects in placental angiogenesis (Table 3) [91, 92] . However, some mice deficient of p38␣ can survive until E16.5, and these embryos exhibit a normal morphology but are anemic as a result of stress-induced abnormal erythropoiesis. Lack of p38 activity was found to interfere with stabilization of Epo mRNA in human hepatoma cells undergoing hypoxic stress, resulting in diminished EPO gene expression [92, 144] . Despite proposed roles for p38MAPK isoforms in various cellular processes, mice deficient of p38␤, p38␥, or p38␦ survive normally and exhibit no pathological changes, indicating redundancy between the various isoforms [93, 94, 145] . In addition, it has been demonstrated that p38MAPK is implicated in the regulation of TEL, a member of the ETS family of transcription factors that plays a critical role in establishment of postnatal hematopoiesis for all lineages in the transition of hematopoietic activity from fetal liver to bone marrow [146, 147] . p38MAPK-dependent phosphorylation of TEL was found to reduce the transcriptional repression abilities of TEL, suggesting that p38MAPK might indeed play a role in regulating neonatal hematopoiesis through suppression of TEL function.
So far, experiments focusing on p38 function in vivo have revealed a critical role for p38 in the regulation of erythropoiesis. Additional ex vivo studies using differentiation-competent cells further established the importance of the p38-signaling module in regulating erythroid and myeloid differentiation [148 -152] (C. R. Geest et al., submitted). Furthermore, functional analysis of p38␣ and p38␤ MAPKs in these cellular processes has been accelerated by the availability of pyridinyl imidazole compounds, such as SB203580, which inhibit p38 isoforms [153] . However, as many studies have relied solely on using these pyridinyl imidazole inhibitors, the relative contribution of the different isoforms in most cellular processes remains unknown.
p38 activation was reported to be induced by EPO [125, 127, 154] , and several reports have suggested that p38 is necessary for the initiation of erythroid differentiation. Pharmacological inhibition of p38 suppressed EPO-induced differentiation of SKT6 cells, and p38 antisense oligonucleotides inhibited Epo-induced hemoglobinization [148] . In contrast, activation of p38 by ectopic expression of a constitutively active MKK6 mutant induced hemoglobinization of SKT6 cells without Epo, indicating that activation of p38 is indeed required for Epo-induced erythroid differentiation. Furthermore, proliferation of human CD34 ϩ -derived erythroid progenitors and several erythroid cell lines was found to be regulated positively by p38MAPK [149 -151] . Interestingly, distinct stage-specific expression patterns of the four p38MAPK isoforms have been described for primary erythroid progenitors during erythroid differentiation [155] . Examination of the mRNA expression patterns of each of the four p38 isoforms during erythroid differentiation of primary erythroid progenitors revealed that p38␣ and p38␥ transcripts are expressed in early hematopoietic progenitors as well as in late differentiating erythroblasts, whereas p38␦ mRNA is only expressed and active during the terminal phase of erythroid differentiation [155] . In contrast, p38␤ was found to be expressed minimally in early CD34ϩ hematopoietic progenitors and absent completely in lineage-committed erythroid progenitors. Despite lack of obvious phenotypes in mice deficient of p38␤, p38␥, or p38␦, these distinct stage-specific expression patterns suggest that the p38MAPK isoforms are not redundant in erythrocyte progenitors and may have distinct functions during erythrocyte maturation.
Besides involvement in the regulation of erythropoiesis, the importance of p38MAPK activity in regulating myeloid differentiation is illustrated by a recent study showing that p38 plays an important role in regulating expansion and differentiation of myeloid progenitors during granulopoiesis (C. R. Geest et al., submitted). Inhibition of p38MAPK was found to enhance neutrophil development, whereas constitutive activation of p38 abrogated neutrophil differentiation completely. Furthermore, in vivo experiments using NOD/SCID mice transplanted with CD34 ϩ cells ectopically expressing constitutively active MKK3 also resulted in reduced neutrophil differentiation. The underlying molecular mechanism was found to involve inhibitory phosphorylation of C/EBP␣ on serine 21 in response to p38MAPK activation. Besides being activated by cytokines that promote proliferation, differentiation, and survival of hematopoietic progenitors, the p38MAPK signaling pathway is also activated by cellular stimuli that exert negative regulatory effects on hematopoiesis. p38MAPK appears to be activated by myelosuppressive cytokines, such as IFN-␣ and -␤, TGF-␤, and TNF-␣ [156 -158] . In human hematopoietic progenitor cells, treatment with IFN-␣ and -␤, TGF-␤, and TNF-␣ resulted in dose-dependent inhibition of myeloid and erythroid colonies in methylcellulose colony-forming assays [156, 158] . In addition, the p38MAPK pharmacological inhibitors SB203580 and SB202190 were found to reverse the growth-inhibitory effects of these cytokines. Additional studies to clarify the molecular mechanism of these observations have indicated that p38 activation indeed is required for IFN-␣-dependent transcriptional activation [159] . On the hand, a study by Kale [160] reported that TGF-␤, when used at low doses, stimulated colony formation from CD34ϩ cells. Low doses were found to induce ERK phosphorylation strongly, whereas high doses induced p38 activation. Furthermore, use of the p38MAPK inhibitor SB203580 along with low TGF-␤ concentrations exhibited a synergistic effect on stimulation of colony formation. These data suggest that dose-dependent, bidirectional effects of TGF-␤ on hematopoiesis may result from differential activation of the p38 and ERK MAPK signaling pathways by TGF-␤.
Bone marrow stromal cells have been demonstrated to play an essential role in the regulation of proliferation and differentiation of hematopoietic stem and progenitor cells [161] . Long-term bone marrow cultures were found to produce essential cytokines, chemokines, and growth factors such as IL-6, IL-11, G-CSF, and GM-CSF. Interestingly, pharmacological inhibition of p38MAPK was found to disrupt the cytokine network between stromal cells and hematopoietic cells through dose-related inhibition of hematopoietic cytokine production, suggesting that p38MAPK-mediated regulation of stromal-derived cytokines might be involved in supporting normal hematopoiesis [162] .
Taken together, these studies suggest an important role for p38MAPK signaling in the regulation of erythropoiesis and myelopoiesis.
ROLE OF MAPK SIGNALING IN HSC MAINTENANCE
Throughout the lifetime of an organism, HSCs are required to self-renew as well as differentiate into the various hematopoietic lineages [163] . Therefore, appropriate control of HSC self-renewal is essential for the maintenance of hematopoietic homeostasis. Recently, MAPK signaling has been demonstrated to play a key role in the maintenance of HSC quiescence [164, 165] . The p38MAPK pathway was found to be constitutively activated in HSCs obtained from mice deficient in the gene encoding Atm, a cell-cycle checkpoint regulator that is also thought to be involved in regulating oxidant levels [164] . Deletion of Atm, resulting in elevated levels of ROS and HSCspecific phosphorylation of p38MAPK, was accompanied by loss of self-renewal capacity and defects in HSC maintenance. Treatment with an antioxidant or p38MAPK inhibitor rescued these mice from bone marrow failure, suggesting that the p38MAPK signaling pathway contributes to HSC exhaustion in response to ROS-mediated oxidative stress. Examination of normal HSCs revealed that a significant fraction of the stem cells was quiescent and in the G0 phase of the cell cycle, whereas ROS-mediated activation of p38 resulted in abrogation of quiescence in HSCs. The connection between oxidants and stem cell aging was supported further by a study reporting that ROS-related oxidative stress abrogates the reconstituting capacity of HSCs, leading to defective self-renewal of HSCs [165] . Recent experiments showed that the ROS low HSC population has a higher self-renewal potential, whereas significant HSC exhaustion was observed in the ROS high population following serial transplantation. p38MAPK activity was higher in the ROS high compared with the ROS low population. Importantly, prolonged treatment of HSCs with the antioxidant or p38MAPK inhibitor extended the lifespan of HSCs in serial transplantation experiments and was able to restore HSC function in the ROS high population, indicating that inactivation of p38MAPK protects HSCs against loss of self-renewal capacity [165] .
In addition, the ERK MAPK signaling pathway has been demonstrated to play an important role in the maintenance of HSC quiescence. A recent report by Oostendorp et al. [166] showed that stimulation of cord blood-derived Lin-CD34ϩCD133ϩ cells with SCF resulted in strong activation of ERK1/2 and rapid induction of proliferation. However, as a single factor, SCF was not able to promote long-term colonyforming activity, indicating that self-renewal requires additional signals. Expansion of Lin-CD34ϩCD133ϩ cells was increased further by the addition of the growth factor oncostatin M (OSM), and OSM was found to cooperate with SCF, not only to promote mitogenic activity but also to preserve the repopulating activity of CD34ϩ cells expanded with SCF. Interestingly, OSM was found to modulate the duration of SCF-induced activation of ERK1/2 specifically, indicating that there was indeed a role for ERK signaling in the regulation of HSC maintenance. Importantly, the effects of OSM could be mimicked by specific inhibition of the MEK-ERK pathway, indicating that the loss of repopulating activity in response to SCF stimulation is counteracted by OSM through down-regulation of ERK1/2. Although the role of JNK signaling for HSC maintenance is undefined currently, these experiments support a role for p38MAPK and ERK MAPK signaling in the regulation of HSC self-renewal and homeostasis.
MAPK SIGNALING AND HEMATOLOGICAL MALIGNANCIES
As MAPK activation plays critical roles in the regulation of proliferation, survival, and differentiation (Fig. 2) , aberrant activation of this pathway could be considered as a likely cause of hematopoietic disease. Over the last decade, extensive work has confirmed the hypothesis that MAPK pathways play critical roles in the pathogenesis of various hematological malignancies. The importance of MEK-ERK signaling in the regulation of hematopoiesis is underscored by constitutive activation of the ERK MAPK pathway in a wide variety of myeloid malignan- Figure 2 . A model summarizing the lineage stagespecific requirement for MAPK activity during hematopoiesis. Inhibition of p38 is essential for neutrophil development, whereas activation is required for eosinophil, monocyte, and erythrocyte differentiation. In addition, activation of ERK is essential for final maturation of erythrocytes and monocytes, whereas initial ERK activity is required for optimal expansion of progenitors during myelopoiesis. Furthermore, p38MAPK and ERK MAPK signaling negatively regulates HSC self-renewal and homeostasis. Although the precise role of the different JNK family members is defined incompletely currently, activation of JNK is important for erythrocyte development. Positive effects on lineage development are depicted in green, and inhibitory effects are depicted in red. CMP, Common myeloid progenitor.
cies [167, 168] . Sustained activation of the MEK-ERK axis has been reported in a majority of AML and CML [70, 169 -172] . For example, Morgan et al. [169] have shown activation of the MEK-ERK pathway in nine of 14 AML cell lines and two of five CML cell lines studied. Expression of a constitutively active form of Raf kinase in hematopoietic cell lines results in MEK activation and growth factor independence [173] . Moreover, inhibition of MEK-ERK activation by pharmacological inhibitors inhibits proliferation and induces apoptosis in AML blasts [174 -177] . Mutations, which are found in up to 30% of AML patients, constitutively activating the FLT3R gene, are also believed to mediate their effects through activation of the downstream MEK-ERK signaling pathway [178] . Activation of FLT3 was found to inhibit C/EBP␣ function by ERK1/2-mediated phosphorylation on serine 21, which may contribute to the observed differentiation block in leukemic blast cells. In human FLT3 mutant AML cells, pharmacological inhibition of MEK1 resulted in granulocytic differentiation, whereas there was no effect when serine 21 was mutated to aspartate, which mimics phosphorylation of C/EBP␣ [178] .
Previously, it has also been reported that MEK1/2 inhibitors markedly enhanced the lethality of the tyrosine kinase inhibitor imatinib mesylate in leukemia cells expressing the BCR-ABL fusion gene, which encodes a cytoplasmic tyrosine kinase that is the underlying molecular cause of CML [179] .
Recently, it has been suggested that these agents interact in a highly synergistic manner to induce mitochondrial injury and apoptosis in resistant CML cells in association with multiple perturbations in survival signaling pathways, including inactivation of Bcr/Abl and ERK1/2, down-regulation of Bcl-xL and Mcl-1, and activation of Bim [180] . Consequently, the combination of dasatinib, a second-generation Bcr/Abl kinase inhibitor that is more active than imatinib mesylate, and MEK1/2 inhibitor PD184352 may have reduced Bcl-xL expression by disrupting activation of the MEK-ERK signaling axis [181] . In addition, expression of Mcl-1 is known to be regulated by MEK-ERK, which therefore, may account for the observed down-regulation of Mcl-1 in dasatinib/PD184352-treated cells [181] . Furthermore, recent studies suggest that Mcl-1 cooperates with Bcl-xL to inactivate proapoptotic Bak [182] . Thus, disruption of Mcl-1 and Bcl-xL expression in cells exposed to the combination of dasatinib and MEK1/2 inhibitor PD184352 could release Bak, thereby triggering mitochondrial dysfunction, culminating in cell death. Recent reports suggest further that ERK1/2-dependent phosphorylation of Bim can inhibit interactions between Bim and Bax, thereby inhibiting its proapoptotic activity and leading to enhanced survival [183] .
Interestingly, our recent observations have revealed that modulating the duration and extent of ERK activation is essential in regulating the balance between expansion and survival of myeloid progenitors (C. R. Geest et al., submitted). Activation of MEK1 in CD34 ϩ cells resulted in increased progenitor expansion; however, in contrast to the effects of constitutive MEK activation in AML blast cells, prolonged MEK1 activation prevented myeloid differentiation as a result of induction of cell death. This suggests that although MEK-ERK signaling may indeed be a critical factor in the generation of myeloid leukemia, additional mechanisms are required for cellular transformation to occur. The central role of the MEK-ERK pathway in sustaining proliferation in a large percentage of myeloid leukemias makes this signaling module a potential target for the molecular therapy. Various studies have demonstrated the beneficial effects of chemotherapeutic agents that inhibit MEK-ERK activation in inducing growth suppression and apoptosis of AML cells [169, 172, 174] .
Although a role for the MEK-ERK signaling pathway in mediating mitogenic and antiapoptotic signals in hematological malignancies has been well established, defects in p38 and JNK MAPK signaling that play a specific role in the regulation of hematological disorders are not well defined. It has been demonstrated recently that p38MAPK regulates cell-cycle checkpoint controls, suggesting that defective p38MAPK function may contribute to cell-cycle defects and tumorigenesis [79, 184, 185] . In various cell types, p38MAPK has been implicated in the suppression of tumorigenesis through inhibition of cell growth by regulating cyclin D levels and inhibiting the activity of Cdc25 [79, 185] . In contrast, p38MAPK was found to be constitutively activated in the bone marrows of patients with MDS [156, 157, 186] . Inhibition of p38MAPK decreased apoptosis and stimulated colony formation of primary MDS progenitors, suggesting that aberrant activation of the p38MAPK pathway may cause differentiation defects. Furthermore, we have demonstrated recently that inhibition of p38MAPK in CD34 ϩ progenitor cells isolated from G-CSF-unresponsive severe congenital neutropenia patients restored neutrophil differentiation, supporting the idea that aberrant activation of the p38MAPK pathway can be involved in the development of specific bone marrow failure syndromes (C. R. Geest et al., submitted).
Despite increasing evidence implicating the JNK pathway in the development of cancer, the mechanistic basis for these findings remains unclear. For example, the BCR-ABL fusion gene has been demonstrated to activate the JNK signaling pathway [187] . Dominant-negative mutants of its downstream effector, the transcription factor c-Jun, were found to impair the transforming capacity of BCR-ABL, suggesting a potential role for the JNK/c-Jun axis in BCR-ABL-mediated transformation of hematopoietic cells. Furthermore, analysis of AML patient cells with specific translocations t(8;21), t(15;17), or inv(16) revealed increased expression levels of c-Jun [188] . In t(8;21)-positive AML cells, the AML1-ETO fusion gene, resulting from the t(8;21) translocation, was found to induce upregulation of c-Jun expression in a JNK-dependent manner, indicating that activation of c-Jun or JNK may promote cellular transformation.
Aberrant activation of FLT3 signaling through mutation or overexpression is also believed to mediate constitutive activation of JNK in a significant number of AML cases [189] . Moreover, another study showed a relationship between constitutive activation of JNK in leukemic blast cells and treatment failure in AML to anthracyclines [190] , and anthracycline compounds are widely used to treat leukemias, and resistance to anthracyclines in AML has been attributed mainly to P-gP, a glycoprotein expressed at the cell surface, which confers resistance to the drug by effluxing it out of the cell. Analysis of 67 AML samples revealed a positive correlation between JNK activity and increased P-gP efflux, suggesting a potential role for the JNK signaling in AML [190] .
However, in vitro exposure of primary AML cells to the anthracycline compound daunorubicin revealed a strong correlation between high JNK activity and the response of patients to standard induction chemotherapy. In this study, failure of JNK activation was found to confer resistance to anthracycline in AML, indicating that daunorubicin-induced apoptosis in AML cells is mediated through JNK activation, which when abrogated, contributes to drug resistance [191] . Taken together, these studies suggest that MAPK pathways play critical roles in the pathogenesis of various hematologic malignancies, providing new, possible molecular targets for future therapeutic approaches.
CONCLUDING REMARKS
It is clear that correct regulation of MAPK signaling is essential in the regulation of multiple processes involved in blood cell production. Extensive work over the last decade has increased our understanding of the mechanisms that are involved in the regulation of normal hematopoiesis. Several studies also support the idea that the ERK MAPK pathway participates in mitogenic responses in various hematological malignancies, whereas the regulatory roles of the JNK and p38MAPK pathways are less well defined and may vary depending on the specific cellular context. Although less is known about the functional roles of p38 and JNK in the regulation of normal and malignant hematopoiesis, they appear to mediate the processes involved in regulating the sensitivity or resistance to various chemotherapeutic agents. Although the precise molecular mechanisms underlying the development of different hematopoietic malignancies upon aberrant activation of the different MAPK signaling modules remain to be investigated, increased understanding of their specific functions has accelerated the development of specific inhibitors that are being clinically evaluated. Further identification of specific MAPK substrates and their role in differentiation, proliferation, and survival of hematopoietic stem and progenitor cells should provide novel therapeutic strategies for the treatment of hematological malignancies and bone marrow failure. 
